期刊文献+

儿童朗格罕细胞组织细胞增生症合并中枢神经系统侵犯临床研究(附98例分析) 被引量:7

Clinical research of Langerhans cell histiocytosis combined with central nervous system involvement(analysis of 98 cases)
原文传递
导出
摘要 目的探讨儿童朗格罕细胞组织细胞增生症(LCH)合并中枢神经系统侵犯的高危因素、临床与影像学特点及预后。方法将首都医科大学附属北京儿童医院2005年1月至2008年12月收治的98例初发LCH患儿分3组进行神经系统症状、体征及头颅MRI检测,并定期监测上述指标以评估疗效,Ⅰ组为多系统危险组(57例),Ⅱ组为多系统低危组(19例),Ⅲ组为单纯骨破坏组(22例)。结果中枢神经系统受累患儿共24例,占24.5%,其中Ⅰ组17例,Ⅱ组7例。19例合并颅面骨破坏;16例出现神经系统症状,其中中枢性尿崩9例。头颅MRI显示受累部位为垂体者共14例次。对中枢受累患儿按LCH-Ⅲ方案联合化疗,目前处于非活动性疾病状态6例,疾病稳定状态10例,疾病进展4例,死亡4例。结论颅面骨破坏、合并危险器官受累是中枢神经系统发病的高危因素。最常见的影像学改变是下丘脑-垂体轴受累。早期及随诊中进行MRI监测非常重要。中枢神经系统一旦出现器质性病变常不可逆,严重影响患儿生活质量。 Objective To study risk factors, clinical and imaging features and prognosis of children LCH combined with central nervous system involvement. Methods We conducted neurological signs inspection, cranial MRI and periodical monitoring and assessment in 98 LCH patients in Bejing Children's Hospital, Capital Medical University during the period of 2005-2008. Then we use SPSS 13.0 software to analyze the log. Results ( 1 ) We found 24 patients having central nervous system involvement, 17 patients in group Ⅰ , 7 cases in group Ⅱ. (2)Totally 19 of them had craniofacial bone destruction, 16 of them had neurological symptoms and 9 had diabetes insipidus. Cranial MRI showed the involvement of pituitary was common and existed in 14 of them. (3) All of the 24 patients were treated by LCH- Ⅲ schema. From then on, 6 of them in non-active status, 10 of them in stable status, 4 of them in progressive status and 4 of them died. Conclusion Violation of CNS is a common combination of LCH. The risk factors of CNS include craniofacial bone destruction and "Risk organ" involvement. The most common imaging change is the hypothalamus-pituitary axis changes. MRI is a very important monitoring method. The central nervous system damaged is irreversible. Once occurring, it will significantly affect the life quality of patients.
出处 《中国实用儿科杂志》 CSCD 北大核心 2010年第9期698-701,共4页 Chinese Journal of Practical Pediatrics
关键词 朗格罕细胞组织细胞增生症 中枢神经系统侵犯 儿童 Langerhans cell histiocytosis central nervous system involvement children
  • 相关文献

参考文献13

  • 1朱佳,方建培.朗格汉斯细胞组织细胞增生症的诊治进展[J].国外医学(儿科学分册),2005,32(6):383-384. 被引量:11
  • 2Gasent BJM ,Alberola CV ,Solano VC ,et al. Langerhans cell histiocytosis [ J ]. C lin Transl Oncol, 2008,10( 11 ) :688-696.
  • 3Dolken R, Weigel S, Schroder H, et al. Treatment of severe disseminated juvenile systemic xanthogranuloma with multiple lesions in the central nervous system [ J ]. J Pediatr Hematol Oncol, 2006,28(2) :95-97.
  • 4Krishna H, Behari S, Pal L, et al. Solitary Langerhans cell histiocytosis of the elivus and sphenoid sinus with parasellar and petrous extensions: case report and review of literature [J]. Surg Neur, 2004,62 : 447-454.
  • 5Cochrane LA, Prince M, Clarke K. Langerhans' cell histiocytosis in the paediatric population: presentation and treatment of head and neck manifestations [J]. J Otolaryngol, 2003, 32: 33-37.
  • 6Grois N, Prayer D, Prosch H, et al. Neuropathology of CNS disease in Langerhans cell histiocytosis [J]. Brain, 2005, 128 (Pt 4) : 829-838.
  • 7Prayer D, Grois N, Prosch H, et al. MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis [ J ]. Am J Neuroradiol, 2004,25 : 880-891.
  • 8Donadieu J, Rolon MA, Pion I, et al. French LCH Study Group. Incidence of growth hormone deficiency in pediatric-onset Langerhans cell histiocytosis: efficacy and safety of growth hormone treatment [ J ]. J Clin Endocrinol Metab, 2004,89: 604-609.
  • 9D' Ambrosio, Stephanie S, Craig W, et al. Craniofacial and intracranial manifestations of Langerhans cell histiocytosis: report of findings in 100 patients [J]. AJR Am J Roentgenol, 2008, 191:589-597.
  • 10Azouz EM, Saigal G, Rodriguez MM, et al . Langerhans' cell histiocytosis : pathology, imaging and treatment of skeletal involvement[J]. Pediatr Radial,2005,35(2) : 103-115.

二级参考文献20

  • 1Arico M, Nichols K, Whitlock JA, et al. Familial clustering of Langerhans cell histiocytosis[J]. Br J Haematol, 1999,107(4): 883-888.
  • 2Pardanani A, Phyliky RL, Li CY, et al. 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis[ J]. Mayo Clin Proc,2003,78(3):301-306.
  • 3Simonart T, Urbain F, Verdebout JM, et al. Langerhans' cell histiocytosis arising at the site of basal cell carcinoma excision[J]. J Cutan Pathol, 2000,27(9) :476-478.
  • 4Dina A,Zahava V,Iness M. The role of vascular endothelial growth factor in Langerhans cell histiocytosis[ J]. J Pediatr Hematol Oncol, 2005,27 (2): 62-66.
  • 5Culic S,Jakobson A, Culic V, et al. Etoposide as the basic and interferonalpha as the maintenance therapy for Langerhans cell histiocytosis: a RTC [J]. Pediatr Hematol Oncol,2001,18(4) :291-294.
  • 6Bank MI, Rengtved P, Carstensen H, et al. Langerhans cell histiocytosis: an evaluation of histopathological parameters, demonstration of proliferation by Ki-67 and mitotic bodies[J] .APMIS,2003,111(2) :300-308.
  • 7Leenen PJ, Egeler RM. Langerhans' cell histiocytosis is caused by dysregulation of the E-cadherin-beta-catenin cascade: a hypothesis [ J ].Immunol Cell Biol, 1999,77(5) :460-467.
  • 8Aslan V, Akay OM, Durak B, et al. Langerhans cell histiocytosis with transformation to acute leukemia showing 45, X, t(8; 21 ), 5q-, -Y karyotype [ J]. Leuk Lymphoma, 2002,43 (8): 1683-1685.
  • 9Robak T, Kordek R, Robak E, et al. Langerhans cell histiocytosis in a patient with systemic lupus erythematosus: a clonal disease responding to treatment with cladribine, and cyclophospharnide[ J]. Leuk Lymphoma, 2002,43 (10):2041-2046.
  • 10Bouloc A, Boulland ML, Geissmann F, et al. CD101 expression by Langerhans cell histiocytosis cells [ J ]. Histopathology, 2000, 36 ( 3 ): 229-232.

共引文献10

同被引文献84

  • 1关丽明,戚喜勋,黄砚玲,徐克,段红杨.脑郎格尔汉斯细胞组织细胞增多症的MRI表现[J].中华放射学杂志,2006,40(2):220-221. 被引量:2
  • 2高举,袁粒星.郎格汉斯细胞组织细胞增生症的诊断和治疗[J].实用儿科临床杂志,2006,21(15):1037-1040. 被引量:22
  • 3Camelo-Piragua S,Zambrano E,Pantanowitz L. Langerhans cell histiocyt [J].ENT:Ear,Nose & Throat Journal,2010,89(3) : 112-113.
  • 4Abla O,Egeler RM,Weitzman S. Langerhans cell histiocytosis:current concepts and treatments[J]. Cancer Treat Rev,2010,36(4):354-359.
  • 5Demaerel P,Gool SV. Paediatric neuroradiological aspects of Langerhans cell histioeytosis [ J ].Neuroradiology, 2008,50 : 85-92.
  • 6Nanduri VR,Pritchard J,Levitt G,et al. Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis [J]. Eur J Cancer,2006,42:2563-2569.
  • 7Gasent BJM,Alberola CV,Solano VC,et al. Langerhans cell histiocytosis [ J ].Clin Transl Oncol, 2008, l0 ( 11 ) : 688-696.
  • 8Varni JW,Seid M,Knight TS,et al. The PedsQLTM4.0 Generic Core Scales:Sensitivity,responsiveness,and impact on clinical decision-making [J]. Journal of Behavioral Medicine,2002,25(2):175-193.
  • 9Vami JW,Limbers C,Burwinkle TM. Literature review:heahh-related quality of life measurement in pediatric oncology:hearing the voices of the children[J]. J Pediatr Psychol,2007,32(9):1151-1163.
  • 10Matziou V,Perdikaris P,Feloni D,et al. Cancer in childhood:Chil- dren's and parents' aspects for quality of llfe [J]. European Journal of Oncology Nursing,2008,12(3),209-216.

引证文献7

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部